<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519518</url>
  </required_header>
  <id_info>
    <org_study_id>923</org_study_id>
    <nct_id>NCT01519518</nct_id>
  </id_info>
  <brief_title>How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention</brief_title>
  <acronym>HEAT-PPCI</acronym>
  <official_title>A Randomised Controlled Trial to Compare Unfractionated Heparin Versus Bivalirudin in the Treatment of Patients With a Clinical Diagnosis of ST-Segment Elevation Myocardial Infarction Events - For Planned Management With Primary PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool Heart and Chest Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liverpool Heart and Chest Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the
      performance and subsequent outcomes of Primary percutaneous coronary intervention. This will
      be a pragmatic trial. Interventional procedures will be performed to reflect current and
      evolving standards, including predominant radial access. All patients will be treated with
      routine oral anti-platelet therapy pre-procedure. GP IIb/IIIa inhibitors will be reserved for
      'bail out' treatment only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HEAT-PPCI is a single-centre prospective, dual-arm, open-label, randomised controlled trial
      comparing two antithrombotic agents in patients undergoing PPCI. All patients presenting to
      the PPCI service at Liverpool Heart and Chest Hospital will be assessed for trial
      eligibility. The patients will be allocated by randomisation in equal proportions to the two
      treatment groups receiving UFH (70 units/kg prior to the procedure) or bivalirudin (bolus of
      0.75 mg/kg prior to the start of the intervention, followed by an infusion of 1.75 mg/kg per
      hour for the duration of the procedure).

      Pre-Specified Subgroup Analyses

        -  Subgroup analyses looking at the impact of access site comparing radial versus femoral
           route

        -  Assessment of the outcomes in diabetic patients receiving oral hypoglycaemic or insulin
           therapy versus all other patients

        -  Comparing the outcomes in patients &lt; or ≥ 75 years of age

        -  Type of p2y12 receptor inhibiting antiplatelet agent (Examples: clopidogrel, prasugrel,
           ticagrelor)

        -  Patients with impaired LV function versus normal LV function

        -  Patients managed with actual or attempted primary PCI versus no immediate PCI procedure
           attempted

      PLATELET FUNCTION SUBSTUDY A substudy will be performed to assess indices of coagulation and
      platelet function studies comparing the impact of heparin or bivalirudin therapy on
      coagulation status at the end of the PPCI procedure. This study will be performed on all
      patients treated between the hours of 0800 and 1600, Monday to Friday. A single blood sample
      taken at the time of general blood sampling for routine clinical screening will be analysed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion Revascularization</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type 3-5 Bleeding According to BARC (Bleeding Academic Research Consortium)Definition</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CKMB Release Following Index Revascularisation Measured With a Single Estimation 12-18 Hours After the Procedure</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Bleeding: Type 2 Bleeding According to BARC (Bleeding Academic Research Consortium) Definition</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis Rate (ARC Definite or Probable)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Illustration, and to Allow Comparison With Existing Trials the Rate of Net Adverse Clinical Events (NACE), Combining the Primary Safety and Efficacy Outcomes</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Thrombocytopenia</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Door-to-first Device Time</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1829</enrollment>
  <condition>Acute ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Unfractionated heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 units/kg body weight intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bivalirudin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>unfractionated heparin</intervention_name>
    <description>70 units/kg body weight intravenous</description>
    <arm_group_label>Unfractionated heparin</arm_group_label>
    <other_name>UFH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
    <arm_group_label>bivalirudin</arm_group_label>
    <other_name>Angiox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting with a suspected myocardial infarction event with PPCI as the
             proposed index reperfusion strategy will be included in the trial

        Exclusion Criteria:

          -  ≤ 18 years of age

          -  Known intolerance, hypersensitivity or contraindication to any trial medication

          -  Active bleeding at presentation

          -  Artificial ventilation, reduced conscious level or other factors precluding the
             administration of oral antiplatelet therapy

          -  Previous enrolment in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rod Stables, MA DM FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Heart and Chest Hospital, Liverpool, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <results_first_submitted>April 7, 2015</results_first_submitted>
  <results_first_submitted_qc>April 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2015</results_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liverpool Heart and Chest Hospital NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr Rod Stables</investigator_full_name>
    <investigator_title>Consultant Cardiologist</investigator_title>
  </responsible_party>
  <keyword>ST elevation myocardial infarction</keyword>
  <keyword>Primary percutaneous coronary intervention</keyword>
  <keyword>Unfractionated heparin</keyword>
  <keyword>Bivalirudin</keyword>
  <keyword>primary angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Unfractionated Heparin</title>
          <description>70 units/kg body weight intravenous
unfractionated heparin: 70 units/kg body weight intravenous</description>
        </group>
        <group group_id="P2">
          <title>Bivalirudin</title>
          <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Bivalirudin: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="914"/>
                <participants group_id="P2" count="915"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="907"/>
                <participants group_id="P2" count="905"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Consent not available</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Unfractionated Heparin</title>
          <description>70 units/kg body weight intravenous
unfractionated heparin: 70 units/kg body weight intravenous</description>
        </group>
        <group group_id="B2">
          <title>Bivalirudin</title>
          <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Bivalirudin: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="907"/>
            <count group_id="B2" value="905"/>
            <count group_id="B3" value="1812"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" lower_limit="54.0" upper_limit="73.8"/>
                    <measurement group_id="B2" value="62.9" lower_limit="53.7" upper_limit="74"/>
                    <measurement group_id="B3" value="63.2" lower_limit="53.9" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="663"/>
                    <measurement group_id="B2" value="647"/>
                    <measurement group_id="B3" value="1310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion Revascularization</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unfractionated Heparin</title>
            <description>70 units/kg body weight intravenous
unfractionated heparin: 70 units/kg body weight intravenous</description>
          </group>
          <group group_id="O2">
            <title>Bivalirudin</title>
            <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Bivalirudin: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion Revascularization</title>
          <units>percentage of total participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="907"/>
                <count group_id="O2" value="905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Type 3-5 Bleeding According to BARC (Bleeding Academic Research Consortium)Definition</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unfractionated Heparin</title>
            <description>70 units/kg body weight intravenous
unfractionated heparin: 70 units/kg body weight intravenous</description>
          </group>
          <group group_id="O2">
            <title>Bivalirudin</title>
            <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Bivalirudin: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
          </group>
        </group_list>
        <measure>
          <title>Type 3-5 Bleeding According to BARC (Bleeding Academic Research Consortium)Definition</title>
          <units>percentage of total participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="907"/>
                <count group_id="O2" value="905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CKMB Release Following Index Revascularisation Measured With a Single Estimation 12-18 Hours After the Procedure</title>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minor Bleeding: Type 2 Bleeding According to BARC (Bleeding Academic Research Consortium) Definition</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unfractionated Heparin</title>
            <description>70 units/kg body weight intravenous
unfractionated heparin: 70 units/kg body weight intravenous</description>
          </group>
          <group group_id="O2">
            <title>Bivalirudin</title>
            <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Bivalirudin: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
          </group>
        </group_list>
        <measure>
          <title>Minor Bleeding: Type 2 Bleeding According to BARC (Bleeding Academic Research Consortium) Definition</title>
          <units>percentage of total participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="907"/>
                <count group_id="O2" value="905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis Rate (ARC Definite or Probable)</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unfractionated Heparin</title>
            <description>70 units/kg body weight intravenous
unfractionated heparin: 70 units/kg body weight intravenous</description>
          </group>
          <group group_id="O2">
            <title>Bivalirudin</title>
            <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Bivalirudin: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis Rate (ARC Definite or Probable)</title>
          <units>percentage of total participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="907"/>
                <count group_id="O2" value="905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For Illustration, and to Allow Comparison With Existing Trials the Rate of Net Adverse Clinical Events (NACE), Combining the Primary Safety and Efficacy Outcomes</title>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Thrombocytopenia</title>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Door-to-first Device Time</title>
        <time_frame>28 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Unfractionated Heparin</title>
          <description>70 units/kg body weight intravenous
unfractionated heparin: 70 units/kg body weight intravenous</description>
        </group>
        <group group_id="E2">
          <title>Bivalirudin</title>
          <description>intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Bivalirudin: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Rod Stables</name_or_title>
      <organization>Liverpool Heart and Chest Hospital</organization>
      <phone>01512281616 ext 1489</phone>
      <email>rod.stables@lhch.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

